The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Kushwaha previously served as Chief Digital & Information Officer at Jubilant Ingrevia Limited
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
